Putting it together, we have:
Scott Kelly in 12/14/21 CC:
Scott Kelly in recent 3/31/22 CC at 14:00:
and from here: https://www.biospace.com/article/releases/cyt...kade-icb-/
taking us back to 10/7/21:
mTNBC remains a target, but will likely get done with a partner in check point inhibitor combo therapy.
Scott Kelly in 12/14/21 CC:
Quote:25: 25 Kelly: We are excited about the Basket Trials. I'll start by saying I just presented at San Antonio Conference December 10th. That was in results wrt mTNBC in combination with carboplatin, CCR5 positive, mTNBC and I tell you, the reason why we are excited about the Basket Trial is that they think that there is a growing acceptance that the Tumor Micro Environment is the next Frontier for Immunotherapy. And I mean this amongst practicing physicians, the academic world, probably as well as big pharma, and I think we are more advanced than this. We've been looking at the mechanism of action in the tumor micro environment and see Leronlimab's impact across multiple different oncologic indications and we also think that we can pair this with a check point inhibitor , chemo, radiation, antibody zero conjugates, as well as maybe even a potential monotherapy in certain patients that don't qualify for other treatments. We think the MOA, with T-Regs. When T-Regs come in, they turn off the immune system. We know that they have a high prevalence of CCR5. We can block that. We can actually maybe leverage the immune system. If we look at macrophage re-polarization, that's another potential opportunity. Our animal studies showed a significant reduction in angiogenesis. I think it was 62% in total vessillary and 80% reduction in small vessel area. But, we know that tumors need a blood supply to grow and if we can help limit that, then we think we can have benefit for patients. And last, we know that normal cells, CCR5 is only present on an immune cell, but we know that when cells under go malignant transformation, that they start sprouting up CCR5, and we believe that is a contributor to metastasis. So we have multiple different mechanisms of action and we continue to find more as we go along that we will be evaluating.
Scott Kelly in recent 3/31/22 CC at 14:00:
Quote:In the study in the use of check point inhibitors , which is funded by CytoDyn, it may represent another potential opportunity in immunotherapy and is moving forward.
Quote:Focus is on Partnerships for immunotherapy combination.
and from here: https://www.biospace.com/article/releases/cyt...kade-icb-/
taking us back to 10/7/21:
Quote:Published: Oct 07, 2021
Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint Blockade
VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a study for treating triple-negative breast cancer (TNBC) with leronlimab in a humanized TNBC xenograft model. This investigator-initiated study is being led by Jangsoon Lee, Ph.D., assistant professor of Breast Medical Oncology Research at The University of Texas MD Anderson Cancer Center .
The study is intended to determine the potential synergistic therapeutic efficacy of leronlimab in combination with immune checkpoint blockade (ICB) to attempt to raise the standard of care for breast cancer patients.
mTNBC remains a target, but will likely get done with a partner in check point inhibitor combo therapy.
5
